PMEF
XERS icon

Point72 Middle East FZE’s Xeris Biopharma Holdings XERS Stock Holding History

Point72 Middle East FZE’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,689
Closed -$8.9K – 2271
2022
Q4 		$8.9K Buy
+6,689
New +$9.44K ﹤0.01% 1740

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Point72 Middle East FZE's XERS Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Xeris Biopharma Holdings (XERS) in Q1 2023, closing a stake of 6,689 shares — an estimated $8.9K sold.

Point72 Middle East FZE first reported a position in XERS in Q4 2022 and held it in 1 quarter. The position peaked at $8.9K in Q4 2022. 92 funds tracked by Wall St. Rank hold XERS as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Xeris Biopharma Holdings position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 6,689 Xeris Biopharma Holdings shares in Q1 2023, an estimated $8.9K.
  • Point72 Middle East FZE first reported a position in Xeris Biopharma Holdings in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Xeris Biopharma Holdings position peaked at $8.9K in Q4 2022.
  • 92 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.